Upstream Bio, Inc. (UPB) Financial Statements
Upstream Bio, Inc. (UPB) reported trailing twelve-month revenue of $3.2M (up 16.0% year on year) and net income of -$156.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$136.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
UPBUpstream Bio, Inc.Follow UPB — free
—
Price chart with a free account
- Market cap
- 150.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 2.4 | 2.9 | 3.2 | |
| Research & development | 63.0 | 136.8 | 145.8 | |
| Operating income | -77.8 | -160.4 | -170.0 | |
| Pre-tax income | -62.8 | -143.4 | -156.5 | |
| Income tax | 0.0 | 0.0 | 0.0 | |
| Net income | -62.8 | -143.4 | -156.5 | |
| Diluted EPS ($) | -5.58 | -2.66 | -2.89 | |
| Diluted shares (mn) | 13.7 | 53.9 | — |
USD millions · SEC XBRL
Upstream Bio, Inc. — questions
- What is Upstream Bio, Inc.'s revenue?
- $3.2M over the twelve months to 2026-06-30, up 16.0% year on year, from its 10-Q and 10-K filings.
- What is Upstream Bio, Inc.'s net income?
- -$156.5M over the twelve months to 2026-06-30.
- What is Upstream Bio, Inc.'s free cash flow?
- -$136.5M over the twelve months to 2026-06-30.
- What are Upstream Bio, Inc.'s diluted earnings per share?
- $-2.89 over the twelve months to 2026-06-30.
Every figure on this page comes from Upstream Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.